VentiRx Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From VentiRx Pharmaceuticals, Inc.
Celgene won the first approval for a drug developed under its aggressive deal-making strategy in 2017 and several potential blockbusters in its partnered pipeline are edging closer to the market. Ozanimod will soon face regulatory approval, but the next-in-line acquired asset GED-0301 had a major setback. Scrip considers the contribution externally derived products have made – and will make – to Celgene’s business.
In back-to-back deals with AstraZeneca and Juno, Celgene has fronted nearly $1.5 billion to become a serious contender in the field of cancer immunotherapy, and is looking to lead in blood cancers.
As more biopharmaceutical companies become profitable and global, tax strategy becomes an increasingly important aspect of deal-making and intellectual property management. Deals of the Week looks at recent tax winners, new tax tactics and potential deal targets that are attractive in part because of their high – or low – tax rates.
Big pharma, small biotech and academic institutions are experimenting with new ways of working together, and San Diego's life science industry group Biocom invited deal makers to town on 26 and 27 February to share their ideas.
- Specialty Pharmaceuticals
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.